<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="125171">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01473004</url>
  </required_header>
  <id_info>
    <org_study_id>10D.95</org_study_id>
    <nct_id>NCT01473004</nct_id>
  </id_info>
  <brief_title>SIR-Spheres® 90Y Microspheres Treatment of Uveal Melanoma Metastasized to Liver</brief_title>
  <official_title>An Open-Label, Single Institution, Phase II Study Using Radioactive Yttrium90 Microsphere (SIR-Sphere®) in Uveal Melanoma Patients With Hepatic Metastasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Cancer Center at Thomas Jefferson University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Thomas Jefferson University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether radiation provided locally to the liver
      tumor vasculature environment will demonstrate a response of tumor decline. This radiation
      may cause the tumor cells to die.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical benefit rate of previously treated and naive patients</measure>
    <time_frame>3 months post final treatment</time_frame>
    <description>Evaluation of clinical benefit includes status of complete and partial response as well as stable disease</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>3 months post final treatment</time_frame>
    <description>Adverse events except for baseline symptoms will be collected from start of first treatment to 3 months post final treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>2 years post treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>2 years post treatment</time_frame>
    <description>Period of time without progression of liver metastasis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>2 years post treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Stage IV Uveal Melanoma</condition>
  <arm_group>
    <arm_group_label>Sirspheres, response evaluation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sir-Spheres® Yttrium-90 microspheres given intra-hepatic; once for each lobe involved separated by 4 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sir-Spheres®</intervention_name>
    <description>Sir-Spheres® Yttrium-90 microspheres given intra-hepatic; once for each lobe involved separated by 4 weeks.</description>
    <arm_group_label>Sirspheres, response evaluation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  must have diagnosis of metastatic melanoma liver disease by histological confirmation

          -  one measurable untreated or progressed liver lesion

          -  less than 50% liver involvement

          -  must have ECOG performance status of 0-1

          -  must have adequate renal and bone marrow function as: serum creatinine ≤ 2.0 mg/dl,
             granulocyte count ≥1000/mm3 and platelet count ≥100,000/mm3

          -  must have adequate liver function as: total bilirubin &lt;1.6 mg/ml and albumin &gt;3.0
             g/dl

        Exclusion Criteria:

          -  failure to meet any of the inclusion criteria

          -  solitary liver metastasis that is amenable to surgical removal

          -  previous treatment with isolated hepatic perfusion

          -  systemic chemotherapy within 2 weeks of study entry

          -  significant shunting to the lung (&gt;20%) as identified on
             Technetium-99m-macro-aggregated albumin nuclear medicine break-through scan

          -  unsuccessful closure of collateral blood flows from the hepatic artery to
             non-targeted organs such as the GI tract

          -  symptomatic liver failure including ascites and hepatic encephalopathy

          -  metastasis outside of liver requiring systemic treatment within 3 months

          -  untreated brain metastasis

          -  main portal vein occlusion or inadequate collateral flow

          -  uncontrolled hypertension or congestive heart failure

          -  acute myocardial infarction within 6 months

          -  medical complications with implication of less than 6 month survival

          -  uncontrolled severe bleeding tendency or active GI bleed

          -  significant allergic reaction to iodinated contrast

          -  previous radiation that includes the liver in the main radiation field

          -  pregnant or breast-feeding women

          -  biliary obstruction, stent, or prior biliary surgery including sphincterotomy but
             excluding cholecystectomy

          -  children under the age of 18
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Takami Sato, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Thomas Jefferson University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carin Gonsalves, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Thomas Jefferson University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Takami Sato, MD</last_name>
    <phone>215-955-8874</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Melanoma Research Group</last_name>
    <phone>215-955-9980</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Takami Sato, MD</last_name>
      <phone>215-955-8874</phone>
    </contact>
    <contact_backup>
      <last_name>Melanoma Research Group</last_name>
      <phone>215-955-9980</phone>
    </contact_backup>
    <investigator>
      <last_name>Takami Sato, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carin Gonsalves, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Eschelman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rani Anne, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>October 19, 2016</lastchanged_date>
  <firstreceived_date>November 14, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sir-spheres</keyword>
  <keyword>Liver Metastases</keyword>
  <keyword>Selective internal radiation</keyword>
  <keyword>Yttrium-90</keyword>
  <keyword>Uveal</keyword>
  <keyword>Melanoma</keyword>
  <keyword>Ocular melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Uveal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
